The ROE as of November 2024 (TTM) for Basilea Pharmaceutica AG (BPMUF) is -385.61%

According to Basilea Pharmaceutica AG’s latest financial reports and current stock price. The company's current ROE is -385.61%. This represents a change of -503.22% compared to the average of 95.63% of the last 4 quarters.

Basilea Pharmaceutica AG (BPMUF) Historical ROE (quarterly & annually)

How has BPMUF ROE performed in the past?

The mean historical ROE of Basilea Pharmaceutica AG over the last ten years is -32.34%. The current -385.61% ROE has changed 1.09% with respect to the historical average. Over the past ten years (40 quarters), BPMUF's ROE was at its highest in in the December 2023 quarter at 213.85%. The ROE was at its lowest in in the September 2015 quarter at -105.97%.

Basilea Pharmaceutica AG (BPMUF) ROE by Quarter and Year

Discovering the peaks and valleys of Basilea Pharmaceutica AG ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Basilea Pharmaceutica AG (BPMUF) Average ROE

How has BPMUF ROE performed in the past?

The current ROE of Basilea Pharmaceutica AG (BPMUF) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Basilea Pharmaceutica AG (BPMUF) ROE vs. Peers

How is BPMUF’s ROE compared to its peers?

Basilea Pharmaceutica AG’s ROE is greater than Ocuphire Pharma, Inc. (-30.19%), less than Reviva Pharmaceuticals Holdings, Inc. (664.92%), greater than Protalix BioTherapeutics, Inc. (-30.89%), greater than EyePoint Pharmaceuticals, Inc. (-43.01%), greater than SELLAS Life Sciences Group, Inc. (-629.45%), greater than ProQR Therapeutics N.V. (-71.11%), less than Alnylam Pharmaceuticals, Inc. (323.66%), greater than Wave Life Sciences Ltd. (-251.35%), greater than Blueprint Medicines Corporation (-47.66%), greater than Apellis Pharmaceuticals, Inc. (-103.92%), less than Moderna, Inc. (0%), greater than CureVac N.V. (-17.68%), less than Novavax, Inc. (21.40%), less than CohBar, Inc. (44.82%), greater than Reata Pharmaceuticals, Inc. (-58.44%), less than BioNTech SE (47.21%), less than Ginkgo Bioworks Holdings, Inc. (-2.38%), greater than CRISPR Therapeutics AG (-70.11%), greater than null (-12.15%),

Build a custom stock screener for Basilea Pharmaceutica AG (BPMUF) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Basilea Pharmaceutica AG using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Basilea Pharmaceutica AG (BPMUF) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Basilea Pharmaceutica AG or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.